Confirmed
50% PSA declinesat week 12 were seen in 18 (55%)
of 33 patients, including nine(47%) of 19
patients with prior ketoconazole therapy and nine
(64%) of 14 patients without prior ketoconazole therapy.
Substantialdeclines in circulating androgens and
increases in mineralocorticoidswere seen with
all doses.
Conclusion Abiraterone acetate was well tolerated
and demonstrated activityin CRPC, including in
patients previously treated with ketoconazole.
Continued clinical study is warranted.
Significant and
Sustained Antitumor Activity in Post-Docetaxel,
Castration-Resistant Prostate Cancer With the CYP17
Inhibitor Abiraterone Acetate
Alison H.M.
JCO Mar 2010:
1489–1495.x`
PSA declines of
30%,
50% and
90% were seen in 68% (32 of47), 51% (24 of 47),
and 15% (seven of 47) of patients, respectively.
Phase II Multicenter
Study of Abiraterone Acetate Plus Prednisone Therapy in
Patients With Docetaxel-Treated Castration-Resistant
Prostate Cancer
Daniel C. Danila, JCO Mar 2010: 1496–1501.
A
50% decline in PSA was confirmed in 22 (36%) patients,
including14 (45%) of 31 ketoconazole-naïve and
seven (26%) of 27ketoconazole-pretreated
patients. Partial responses were seenin four
(18%) of 22 patients with RECIST-evaluable target lesions.Improved ECOG PS was seen in 28% of patients. Median
time toPSA progression was 169 days
50% PSA declines at week 12 were seen in 18 (55%)
of 33 patients, including nine (47%) of 19
patients with prior ketoconazole therapy and nine
(64%) of 14 patients without prior ketoconazole therapy.
Substantial declines in circulating androgens and
increases in mineralocorticoids were seen with
all doses.